8 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 11 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Recruiting 8, Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow CRC (Colorectal Cancer): new trials by email Literature Review of CRC (Colorectal Cancer) trials Research Report on CRC (Colorectal Cancer)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) - NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 152 | 2026-11-01 | 2026-11-02 |
| A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer Mitomycin-PIPAC, Raltitrexed-PIPAC - Peritoneal Metastasis, CRC (Colorectal Cancer) | Phase 1 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 42 | 2026-01-01 | 2026-01-16 |
| A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation GFH375 - Advanced Solid Tumors Cancer, PDAC | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 126 | 2025-10-21 | 2025-12-02 |
| A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors GFH276 - Cancer, PDAC | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 450 | 2025-09-22 | 2025-09-30 |
| A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors ALX2004 - NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC | Phase 1 | Recruiting | ALX Oncology Inc. | 170 | 2025-08-18 | 2026-09-30 |
| A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors TGI-5 - CRC (Colorectal Cancer), Melanoma (Skin Cancer) | Phase 1 | Recruiting | Hefei TG ImmunoPharma Co., Ltd. | 194 | 2025-06-12 | 2026-01-29 |
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin) - Non-Small Cell Lung Cancer, NSCLC | Phase 1 | Recruiting | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 665 | 2025-03-31 | 2026-06-02 |
| A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations ALTA3263, cetuximab, mFOLFOX6 - Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Alterome Therapeutics, Inc. | 448 | 2025-03-05 | 2026-10-26 |
| A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies KQB365, Cetuximab, KQB198 - KRAS G12C Mutation, KRAS G12S Mutation | Phase 1 | Recruiting | Kumquat Biosciences Inc. | 140 | 2025-02-04 | 2026-11-03 |
| Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors Decoy20, Tislelizumab - Solid Tumor, Adult, HCC - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Indaptus Therapeutics, Inc | 120 | 2023-02-28 | 2026-01-13 |
| Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung Cancer iNeo-Vac-P01 - CRC (Colorectal Cancer), Non Small Lung Cancer | Phase 1 | Completed | Ying Yuan, MD | 6 | 2020-10-30 | 2026-03-31 |
Colorectal Neoplasms (11) · Carcinoma, Non-Small-Cell Lung (7) · Neoplasm Metastasis (3) · Carcinoma, Hepatocellular (2) · Colonic Neoplasms (2) · Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasms by Site (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
Colonic Diseases (11) · Digestive System Diseases (11) · Digestive System Neoplasms (11) · Gastrointestinal Diseases (11) · Gastrointestinal Neoplasms (11) · Intestinal Diseases (11) · Intestinal Neoplasms (11) · Rectal Diseases (11) · Neoplasms by Site (10) · Neoplasms (9) · Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7) · Lung Diseases (7) · Respiratory Tract Diseases (7) · Respiratory Tract Neoplasms (7)
Cetuximab (4) · Carboplatin (2) · Cisplatin (2) · Gemcitabine (2) · Pemetrexed (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Midazolam (1) · Nivolumab (1) · Taxes (1) · Therapeutics (1) · X-Rays (1) · tislelizumab (1)
Genfleet Therapeutics (Shanghai) Inc. (2) · ALX Oncology Inc. (1) · Aktis Oncology, Inc. (1) · Alterome Therapeutics, Inc. (1) · Hefei TG ImmunoPharma Co., Ltd. (1) · Indaptus Therapeutics, Inc (1) · Kumquat Biosciences Inc. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (1) · Ying Yuan, MD (1)
United States (6) · China (5) · Australia (1)
Hongxia Wang, Doctorate (1) · Lin Shen, MD (1)